Subcutaneous injections of Pro 140, a monoclonal antibody that blocks the entry of HIV em células, foi bem tolerada e manteve a viral load indetectável por mais de um ano após a suspensão da terapia anti-retroviral (ART) em pessoas com supressão viral, de acordo com um estudo apresentado no ASM Microbe 2016 last week in Boston.
O HIV utiliza dois coreceptores – CCR5 e os receptores CXCR4 – juntamente com o receptor de superfície de células CD4 para inserir -se nas células. PRO 140 é um anticorpo monoclonal humanizado que funciona bloqueando o CCR5, impedindo assim o HIV entre em células e comecem a replicar. Cerca de 70% das pessoas com HIV nos EUA e até 90% de pessoas recém-diagnosticados, tem o HIV com tropismo (atração) pelo receptor CCR5.
Previous studies have shown that a single intravenous injection of PRO 140 dramatically reduced HIV levels and a weekly subcutaneous injection resulted in a significantly higher viral load reduction than placebo. The results suggest that pro 140 does not negatively affect the normal immune functions mediated by CCR5.
PRO 140 antibody was first developed by Progenics but was acquired by CytoDyn in 2012. Data from clinical trials with Pro 140 have not been submitted to scientific conferences or medical journals for several years, but CytoDyn has issued numerous press releases demarcating your progress.
Paulo Maddon, a scientific advisor at CytoDyn, presented findings from an 2B phase of the 140 Pro study as maintenance therapy for people who had achieved viral suppression in standard combination ART.
The CD01 study included 39 HIV-positive adult patients exclusively with tropic HIV to CCR5 (according to Coreceptor DNA tropism analysis), viral load below 40 copies / ml on a stable surface and a T-cell ART regimen CD4 counts up 350 cells / mm3. Over 90% were men with a median age of 55 years.
All participants in this open study switched over a week of overlap from their ART regimen to the weekly application of subcutaneous injections of 350mg from PRO 140 in a monotherapy regimen for up to twelve weeks. Those who had viral rebound restarted ART.
Among the 28 patients in the long-term treatment cohort, 15 people who maintained viral suppression for twelve weeks were trained to self administer their injections (Translator's note: It's easy to do, I do it with another medication twice daily) and allowed to proceed with maintenance therapy by PRO 140 for an additional increment of 108 weeks in an extension phase. In this group 87% were men, 20% were non-white, the mean age was 55, the median CD4 count was 586 cells / mm3 and they had been diagnosed with HIV for an average of 13 years ago.
Of these 15 participants, 10 are still on PRO 140 without ART for over a year - and in some cases approaching two years. Among people tested with a single HIV RNA assay, the lowest viral load average was 0,4 copies / ml.
Of the remaining participants, four had virologic failure (two consecutive measurements of> 400 copies / ml) and restarted ART, while a left the study with undetectable viral load in 47 weeks.
Participants had no evidence of drug resistance, those with virologic failure did not experience a change in HIV tropism in patients who - allowed the virus to enter using CXCR4 receptors instead of CCR5 coreceptors - and no one developed antibodies against the antibody. PRO 140. All participants who restarted ART recovered full viral suppression.
PRO 140 was generally safe and well tolerated. Although overall adverse events were common (more than 90% in the extension phase), there were no drug related or serious adverse events or treatment withdrawal for this reason. All medication-related adverse events were local reactions to the injection, usually mild or moderate.
"For [over] one year, subcutaneous weekly application of PRO 140 350mg since full viral suppression has been well tolerated and has allowed for the avoidance of potential ART toxicity while preserving drug options," the researchers concluded. “These results support further development of Pro 140 SC as a single, long-term maintenance therapy agent. "single" after the first ART in selected HIV-1 patients. ”
They noted that the extension phase of the ongoing study with a plan to further extend monotherapy with the PRO 140 in addition to 120 weeks for patients with continued viral suppression.
Posted in: 28 June 2016
Translated by Claudio Souza in 28 / 06 / 2016 - Published not yet revised given the importance of the fact
Is news that follows, gives us highest hopes for PRO - 140 Antibodies
Lalezari J et al (Maddon P present). PRO 140 SC monotherapy provides long-term and complete virological suppression in HIV patients. ASM microbe, 2016.
- Long-acting oral antiretroviral MK-8591 could represent 'paradigm shift' in HIV treatment and prophylaxis01 April 2016
- Combination inhibitor BMS-986197 demonstrates good activity against HIV in early study18 March 2016
- TAF / emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity25 February 2016
- Dose-finding trials of antibody-based drugs for HIV prevention will start soon24 February 2016
Related news selected from other sources
- The HIV Treatment PipelinePoz - 9 hours ago
- Gilead's single tablet regimen Odefsey receives European marketing approval for HIV treatmentPharmaBiz - 27 June 2016
- Investigational Integrase Inhibitor Bictegravir Safe and Effective Against HIV in Early StudyThe Body - 21 June 2016
- Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 TrialBiotech Border Press Release - 07 June 2016